A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 28 Aug 2023

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Enfortumab vedotin (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary) ; Sitravatinib (Primary)
Indications Carcinoma; Urogenital cancer
Focus Therapeutic Use
Sponsors Mirati Therapeutics

03 Aug 2023 Status changed from Completed to Discontinued.
07 Feb 2023 Status changed from recruiting to Completed.
23 Sep 2020 Protocol amended to add cohort Sitravatinib in combination with Pembrolizumab and Enfortumab vedotin. Planned number of patient and number of arms changed, as reported by ClinicalTrial.gov record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com